Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
|
|
- Brendan Hoover
- 5 years ago
- Views:
Transcription
1 Gan GG Department of Medicine University Malaya Medical Centre Kuala Lumpur
2 outline Definitions Genetic polymorphisms and drugs therapy a)warfarin b) Mercaptopurine c) Methotrexate d) Clopidogrel e) others
3 Definitions Genetic polymorphisms-difference in DNA sequence among individuals, groups or populations that gives rise to different forms e.g. human blood groups Single nucleotide polymorphisms--variation in a single base in the genetic code between different individuals Haplotypes a set of closely linked genetic markers on one chromosome that tend to inherit together Pharmacogenomics-Genetic variation on drug response by correlating gene expression or SNPs with drugs efficacy and toxicity Pharmacodynamics-study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of their actions and effects with their chemical structure Pharmacokinetics--The process by which a drug is absorbed, distributed, metabolized, and eliminated by the body
4 Pharmacogenomics Rationalised the use (individualised) and optimising the drug in relation to patients genotype to ensure maximum efficacy and minimised toxicity Genetic information has been used to identify disease risk (e.g. BRCA1); choice of treatment and drug dose
5 Warfarin narrow therapeutic window large interpatient variability influenced by environmental factors, age, dietary intake and ethnicity Asian patients required a lower dose compared to the African and Caucasian patients
6 Warfarin is a racemic mixture of S-warfarin and R-warfarin Warfarin inhibits the action of vit K epoxide reductase Reduced Vit K is a cofactor for post-translational γ- carboxylation of glutamic acid in coagulation factors VKORC1 gene-vit K epoxide reductase complex subunit1 responsible for metabolism of vit K Gage 2006
7 3 genes involved in metabolism and pharmacodynamic response CYP2C9 VKORC1 CYP4F2
8 CYP2C9 CYP2C9*2 and *3 associated with increased bleeding complications and also lower dose requirement Gage 2006
9 Local Malaysian data on CYP2C9 Gan 2004
10 Ngow 2009
11
12 VK Reider NEJM SNPs to infer haplotypes (position 861, 5808, 6853, 9041) H1 and H2 lower dose and H7and H9 higher dose ( 2.9 vs 3 vs 6 vs 5.5mg) Haplotype AA mean dose 3.2mg; AB dose 4.4mg and BB 6.1mg VKORC1 haplotype predict 21-25% of dose variance in caucasian population compared to CYP2C9 (6-10%)
13
14 Veenstra 2005, Larramendy-gozalo 2006
15 Lee 2006
16 Local Malaysian data for VKORC1
17 VKORC1 gene accounts for 30% CYP2C9 accounts for 12% CYP4F2 accounts for 1.2% Dose variance Takeuchi 2009
18 Loading dose? Should be individualised Complications Algorithm
19
20 Metabolism pathway Commonly used in ALL treatment (part of maintenance therapy) Activated to 6 thiogunaninenulceotides(tgn) by hypoxanthine guanine phosphoribosyl transferase TPMT(thiopurine methytransferase) inactivates 6MP and decreases formation of active TGN in hematopoietic tissue TPMT activity has been showned to correlate with 6MP toxicity and therapeutic efficacy
21 Trimodal activity of TMPT 90% high; 10% intermediate and 0.3% low or undetected The higher activity associated with less toxicity but increase relapse Heterozygote individual intermediate activity (10-11% white caucasians) and homozygous mutant ( %) causing low activity Identify 21 variations in TPMT but 17 showned to reduce TPMT activity TPMT*2,*3A,*3C account for 90% of intermediate or low TPMT activity Thereby screening these 2 polymorphisms can reduce toxicity
22
23 Br j clin pharmacol 2004 J pediatric hematol/oncol 2002
24 Led to change in 6MP labelling in 2004 with TPMT testing and dosage recommendation for those with deficient TPMT activity Found to cost saving in 4 European countries (Germany,Ireland, UK and Netherlands) Limited to only few academic centres includes st judes children hospital
25 Methotrexate (MTX) At oral dose <20mg/m2,bioavailability 50-90% & half life 4-6 hours and excreted unchanged in urine High dose some metabolised 7-hydroxy MTX by hepatic aldehyde oxidase, small proportion metabolised to inactive metabolite (4 amino-4 deoxyn-methylpteroic acid DAMPA) Active compound methotrexate polyglutamates Blocked DNA synthesis - mucositis, marrow suppression, leukemic cell death, liver toxicity and neurotoxicity, renal toxicity Predicting MTX toxicity dosage;renal function;hydration; alkalinisation; use of leucovorin rescue; coadministration of other anticancer agents; pharmacogenetics
26 Genetic polymorphism has been described in all enzymes involved Important enzymes MTHFR (5,10 methylenetetrafolate dehydrogenase) and TYMS (thymidylate synthetase); and possible DHFR (dihydrofolate synthetase)
27 Krajinovic 2004
28 Genotype 520 children with ALL MTHFR has 3 functional functional polymorphism (C677T and A1298G) Frequencies varies within ethnic groups C677T variant allele present in caucasians (34%) & African American (14%) A1298G present in caucasians 27-36% and little data on African American MTHFR C677T variant allele associated with relapse risk (p=0.036) Aplenc 2005
29 Pharmacogenetic-dynamic associations with MTX can only interpreted with specific protocol adjusting for folate dietary intake Genetic variations in folate and antifolate pharmacology affect not only adverse reaction but also relapse rate Need further studies
30 Plavix gets new FDA warning WASHINGTON Fri Mar 12, :01pm EST Related News UPDATE 2-Plavix gets new U.S. FDA warning Fri, Mar UPDATE 1-Plavix gets new U.S. warning on poor responders Fri, Mar WASHINGTON (Reuters) - The blockbuster anti-clotting drug Plavix will carry a new warning about patients who have a poor response to the drug because they do not break it down well, U.S. regulators said on Friday. The Food and Drug Administration said it was adding a new boxed warning to Plavix, an $8-billion-a-year drug sold by Bristol-Myers Squibb Co and Sanofi-Aventis SA. The new language will "warn about reduced effectiveness in patients who are poor metabolizers of Plavix," the FDA said in a notice on its website. Poor metabolizers are people whose bodies do not effectively convert Plavix to its active form. "Because the patient makes less of the active form there is less anti-platelet effect in the blood and the patient may not receive the full benefit of Plavix treatment," Mary Ross Southworth of the FDA's Center for Drug Evaluation and Research told reporters in a teleconference. An estimated 2 percent to 14 percent of the population are poor metabolizers of Plavix, the FDA said.
31 Study population Amish and sinai hospital of Baltimore (62% white, 37% african american)
32 Hematologica 2009
33
34 Others Tamoxifen CYP2D6, CYP2C19 metabolises tamoxifen (breast cancer) Poor metaboliser for CYP2D6 respond worse with tamoxifen (higher recurrence;less hot flushes) Interethnic differences poor metabolisers found mainly in Europe and ultrarapid metabolizers in North Africa and Oceania; intermediate in Asians CYP2C19*2 respond better to tamoxifen compared to wild type Irinotecan used for lung and colon cancers 30% has unacceptable side effects (neutropenia and diarrhoea) Metabolised to more active metabolite SN-38 UGT1A1 ( UDPgluconosyltransferase 1A1) conjugates SN38 to inactive compound UGT1A1 *28 homozygous associated with decreased UGT1A1 expression and hence has more side effects
35 Aspergillus infection Polymorphism in gene which encodes innate immune system which may affect host defense system against IFI Gene looked at not just for recipients but also donors SNPs at Toll-like receptor(tlr4 gene), CXCL-10, TLR1,TLR6, IL1,IL10 and TNFα all been implicated TLR4 1063G and 1363T are virtually absent in Asian population compared to the Caucasian and African American
36
37
38 Cautions Understand the genetic and nongenetic factors Caution- self reported ethnicity maybe imprecise Social implications JCO 2006
39
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development
Warfarin Dosing Using Genetic Information A Model for Hospital Policy Development Jean Lopategui, MD Director, Molecular Pathology Jean.lopategui@cshs.org Warfarin Pharmacogenomics Part I Background Information
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationTailoring Drug Therapy Based on Genotype. Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice
Tailoring Drug Therapy Based on Genotype Larisa H. Cavallari, Pharm.D. Associate Professor, Department of Pharmacy Practice University of Illinois at Chicago 833 S. Wood St., Rm 164 Chicago, IL 60612 Tel:
More informationPage 61 PHARMACOGENETIC AND TUMOUR DRUGS. Table 1. Genetic polymorphisms known to affect responses to anticancer drugs.
PHARMACOGENETIC AND TUMOUR DRUGS polymorphisms known to affect responses to anticancer drugs are presented in Table 1. Table 1. Genetic polymorphisms known to affect responses to anticancer drugs Elizabeta
More informationPharmacogenetics: DNA analysis. to explain / predict. response to drug therapy. Maurizio Ferrari & Ron van Schaik
Maurizio Ferrari & Ron van Schaik Workshop IFCC Kuala Lumpur November 19, 2012 Predictive, Preventive and Personalized Medicine Part II: Pharmacogenetics l r.vanschaik@erasmusmc.nl Pharmacogenetics: DNA
More informationThiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency
Thiopurine S-Methyltransferase (TPMT): Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Approximately 10% of patients have a (an) TPMT phenotype. a) Normal/high function b) Intermediate
More informationPHARMACOGENETICS. Marshalling the human genome to individualize drug therapy
PHARMACOGENETICS Marshalling the human genome to individualize drug therapy Prof. Ronen Loebstein Institute of Clinical Pharmacology & Toxicology Sheba Medical Center Some examples of drug response rates
More informationMedical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR PATIENTS TREATED WITH IRINOTECAN Policy Number 2.02.
Page: 1 of 5 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title GENOTYPING URIDINE DIPHOSPHATE GLYCURONOSYLTRANSFERASE (UGT1A1) FOR Policy Number 2.02.34 Category Laboratory Tests Effective Date
More informationYes if indicated below. (4.0 TMPT does not require prior authorization)
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Prior Authorization Required: Additional Information: Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes if indicated
More informationLecture 3: Antimetabolites cell cycle specific (S-phase) 1. Folate analogs
Lecture 3: Antimetabolites cell cycle specific (S-phase) All the antimetabolites mimic endogenous molecules. They trick enzymes involved in the synthesis of DNA, and instead of metabolizing the proper
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationSLCO1B1 Pharmacogenetic Competency
SLCO1B1 Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 Which of the following is not currently a recognized SLCO1B1 phenotype? a) Low function b) Normal function c) Intermediate function
More informationUtility of Pharmacogenomics to Identify and Limit CV Risk. Christopher B. Granger, MD
Utility of Pharmacogenomics to Identify and Limit CV Risk Christopher B. Granger, MD Disclosure Research contracts: AstraZeneca, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company, and Boehringer
More informationUridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Pharmacogenetic Competency
Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Pharmacogenetic Competency Updated on 7/2015 General Tips for Viewing Material Upon completion of the educational material, close out the presentation
More informationNew Horizons in Anticoagulation: The Way of the Future. Disclosure. Outline. The speaker has nothing to disclose in relation to this presentation
New Horizons in Anticoagulation: The Way of the Future Gloria Grice Pharm.D., BCPS St. Louis College of Pharmacy & Barnes-Jewish Hospital Anticoagulation Service Disclosure The speaker has nothing to disclose
More informationThe Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (5), Page 6646-6654 The Impact of "CYP2C9" and "VKORC1" Genetic Polymorphism upon Oral Anticoagulation Requirements Hossam Yousef Kamal
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationApplication of Pharmacogenetics Supplementary Worksheet
Application of Pharmacogenetics Supplementary Worksheet Section 1 Health Care Problem Section 2 Drug Metabolism Section 3 Phase I & II metabolism Section 4 Inhibitors and Inducers Section 5 DNA & Drug
More informationGenetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
More informationDihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency
Dihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 A patient has a reported pharmacogenetic test result of DPYD *1/*2. What is the assigned phenotype?
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 12/16/10, 12/15/11, 12/20/12, 12/19/13, 12/18/14
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationMEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9 (CYP2C9) AND VITAMIN K EPOXIDE REDUCTASE SUBUNIT CI (VKORC) THAT AFFECT RESPONSE TO WARFARIN
MEDICAL POLICY SUBJECT: GENOTYPING CYTOCHROME P450 2C9, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationTwo decades of clinical pharmacogenetic testing - Where do we stand?
Two decades of clinical pharmacogenetic testing - Where do we stand? Marja-Liisa Dahl, MD PhD, Professor Dept of Clinical Pharmacology Karolinska University Hospital/Karolinska Institutet Stockholm, Sweden
More informationPharmacogenomics and Pharmacokinetics ^
Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning
More informationAcknowledgments. Variation in Drug Response 7/15/2015. Personalized / Precision Medicine: Genomes Guiding Treatment
Personalized / Precision Medicine: Genomes Guiding Treatment Sharon E. Plon, MD, PhD Professor Baylor College of Medicine splon@bcm.edu Acknowledgments Many of the slides shown today were created by Teri
More information2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market
Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationPredict GENES. Select right drug. Select right dose. Develop new drugs. Non-Response Response Adverse Reaction
Predict Select right drug Select right dose Develop new drugs GENES Non-Response Response Adverse Reaction Phase I: Each Chromosome Has Many Genes Chromosome 12 ~ 1,300 Genes Examples of Personalized Medicines
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationExperimental and clinical pharmacology. Pharmacogenetics of warfarin is testing clinically indicated?
Experimental and clinical pharmacology Pharmacogenetics of warfarin is testing clinically indicated? Jennifer H Martin, Clinical Pharmacologist and General Physician, Departments of Medicine and Chemical
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationImplementing Pharmacogenetic Testing Into Clinical Laboratories. Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories
Implementing Pharmacogenetic Testing Into Clinical Laboratories Elaine Lyon, PhD, & Gwen McMillin, PhD University of Utah ARUP Laboratories Key learning objectives Recognize decisions in implementing pharmacogenetic
More informationResearch Article Potential dose-adjustment parameters during 6MP/MTX-therapy for Acute Lymphoblastic Leukemia
Cronicon OPEN ACCESS PAEDIATRICS Research Article Potential dose-adjustment parameters during 6MP/MTX-therapy for Acute Lymphoblastic Leukemia Anahita Mobargha* Department of Paediatrics, Copenhagen, Denmark
More informationHaplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis
Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity
More informationLecture 4: Antimetabolites cell cycle specific (S-phase) 1. Folate analogs
Lecture 4: Antimetabolites cell cycle specific (S-phase) All the antimetabolites mimic endogenous molecules. They trick enzymes involved in the synthesis of DA, and instead of metabolizing the proper endogenous
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationPharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 SCT Plenary 4 Thursday March 30, 2017 Pharmacogenetics to tailor Drug Exposure and Outcomes in Kidney Transplantation Dennis A. Hesselink
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationPharmacogenomic progress in individualized dosing of key drugs for cancer patients
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients Christine M Walko and Howard McLeod* REVIEW SUMMARY Determining the correct dosage for the majority of traditional chemotherapeutic
More informationpatient response to the drug therapy. Treatment for most common form of childhood cancer
Becich 1 Michael Becich Genomics & Medicine Dr. Douglas Brutlag 4 December 2014 Abstract: The field of pharmacogenomics seeks to rationally optimize medication efficacy and minimize adverse effects by
More informationPharmacogenetics and pharmacogenomics of anticancer agents R. Stephanie Huang and Mark J. Ratain. DOI: /caac.20002
Pharmacogenetics and pharmacogenomics of anticancer agents R. Stephanie Huang and Mark J. Ratain CA Cancer J Clin 2009;59;42-55 DOI: 10.3322/caac.20002 This information is current as of March 2, 2009 The
More informationFigure 1. Stepwise approach of treating patients with rheumatoid arthritis.
Establish diagnosis early Document baseline disease activity and damage Estimate prognosis Initiate therapy Begin patient education Start DMARD therapy within 3 months Consider NSAID Consider local or
More informationPharmacogenomic effects on therapy for acute lymphoblastic leukemia in children
CLINICAL IMPLICATION The Pharmacogenomics Journal (2003) 3, 128 135 & 2003 Nature Publishing Group All rights reserved 1470-269X/03 $25.00 Pharmacogenomic effects on therapy for acute lymphoblastic leukemia
More informationLecture 10: Antimetabolites cell cycle specific (S-phase)
Lecture 10: Antimetabolites cell cycle specific (S-phase) bjectives: 1. Be able to explain the general mechanism of action of antimetabolites 2. Understand the specific mechanisms of the folate analogs
More informationClinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity
Clinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity Clinical Policy Number: 02.01.13 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review
More informationSystemic Medications for the Dermatology Toolbox: Azathioprine
Systemic Medications for the Dermatology Toolbox: Azathioprine Wynnis Tom, M.D. Associate Clinical Professor University of California, San Diego and Rady Children s Hospital Faculty Disclosure Information
More informationUSING GENETICS TO DRIVE TREATMENT: A FOCUS WARFARIN
Volume 23, Issue 10 July 2008 USING GENETICS TO DRIVE TREATMENT: A FOCUS ON WARFARIN Gregory J. Welder, Pharm.D. candidate The use of genetics in health care has become a mechanism for identifying risk.
More informationAnticoagulant Treatments for Special Patient Populations
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/anticoagulant-treatments-for-special-patientpopulations/3796/
More informationBackground. Methotrexate Pharmacokinetic and Clinical Review. Therapeutic Uses
Methotrexate Pharmacokinetic and Clinical Review Weak dicarboxylic acid pka 4.8 and 5.5 5 Background Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy Specialist Background MW 454.46 Analog of
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationReview of Pharmacogenetic Testing Today
Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The
More informationSupplementary Text. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Supplementary Text Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry Takaya Moriyama a, Yung-Li Yang b, Rina Nishii a, c, Hany Ariffin
More information6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES
6. DOSE ADJUSTMENTS BASED ON PHARMACOGENETICS OF CYP450 ENZYMES Ron H.N. van Schaik Dept. Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands 6.1 Introduction In today s medicine, drug therapy represents
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_5_fluorouracil_use_in_cancer_patients 1/1/2019 NA 1/1/2020 1/2019 Policy Effective April
More informationDemystifying Pharmacogenetics: its evolution and challenges. June 15, 2016
Demystifying Pharmacogenetics: its evolution and challenges June 15, 2016 Welcome! Dr. Brendan Byrne Chief Innovation Officer, TELUS Health Karen Kesteris Director, Product Management, TELUS Health 2 Today
More informationPharmacogenomic Testing for Warfarin Response (NCD 90.1)
Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationEthnic differences which may affect safety/tolerability. Konstanze Diefenbach 23. AGAH-Annual Meeting (13 March 2014)
Ethnic differences which may affect safety/tolerability Konstanze Diefenbach 23. AGAH-Annual Meeting (13 March 2014) Contents Ethnic factors Introduction into ICH-E5 Definition of ethnic factors Sensitivity
More informationPharmacogenomics: Assessment of Therapeutic Risk vs Benefit
Pharmacogenomics: Assessment of Therapeutic Risk vs Benefit Lawrence J. Lesko Clinical Professor Center for Pharmacometrics and Systems Pharmacology University of Florida at Lake Nona November 15, 2016
More informationHypertension Clinical Trials. in China. Liu Lisheng
Hypertension Clinical Trials in China Liu Lisheng Necessity of Conducting Large-scale Clinical Studies using Chinese Subjects RCT in China Discussion Experience Pharmacogenetics & individualized medicine
More informationReview Article. Pharmacogenetics and anaesthesia: the value of genetic profiling. Summary. The history of pharmacogenetics related to anaesthesia
doi:10.1111/j.1365-2044.2011.06918.x Review Article Pharmacogenetics and anaesthesia: the value of genetic profiling R. Landau, 1 L. A. Bollag 2 and J. C. Kraft 3 1 Professor of Anaesthesiology, 2 Assistant
More informationPharmacogenomics of Cardiovascular Pharmacotherapies
Pharmacogenomics of Cardiovascular Pharmacotherapies Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA University of Florida Gainesville, Florida Pharmacogenomics of Cardiovascular Pharmacotherapies
More informationMembership Overview: Total Members: 322 Student Members: 160 Resident Members: 8 Fellow Members: 4
A Closer Look at the Central Nervous System PRN Overview of the PRN The Central Nervous System Practice and Research Network (CNS PRN) provides a forum to encourage networking among pharmacists specializing
More informationSan Filippo Neri Hospital- Rome
Pharmacogenetics in Breast Cancer Giampietro Gasparini, MD San Filippo Neri Hospital- Rome TUMOR PATIENT Few histotypes but more molecular diseases Pharmacogenomics DRUG Age and PS Comorbidities Compliance
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationGENETICS OF STROKE: GETTING UP CLOSE AND PERSONAL December 8, 2017
GENETICS OF STROKE: GETTING UP CLOSE AND PERSONAL December 8, 2017 1 Faculty Disclosure Faculty: Guillaume Paré MD, MSc, FRCPC Associate Professor, McMaster University Senior Scientist, Population Health
More informationPharmacogenomics: Increasing the safety and effectiveness of drug therapy
Pharmacogenomics: Increasing the safety and effectiveness of drug therapy Introduction to personalized medicine The goal of personalized medicine is to individualize health care by using knowledge of patients
More informationSimon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of
Cardiovascular pharmacogenomics: ready for prime time? Simon de Denus, pharmacist, MSc (Pharm), PhD Université de Montréal Beaulieu-Saucier Chair in Pharmacogenomics Assistant professor, Faculty of Pharmacy,
More informationCancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018
Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationThe role of pharmacogenetics in drug-induced toxicity
The role of pharmacogenetics in drug-induced toxicity Is there anybody today who does not use any medication? The total turnover of pharmaceutical care in the Netherlands in 2014 was 4.3 billion euros.
More informationPrior to starting the webinar. PharmGenEd : Bridging the Gap Between Science & Practice. Disclaimer. Train-the-Trainer Agenda 6/17/2014
Prior to starting the webinar Please make sure you have audio AND web features For audio, dial 866-740-1260 Enter access code 8223833 For video, go to www.readytalk.com Enter access code 8223833 To obtain
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationShould Gene+cs Influence Medica+on Use? Mona Fiuzat, PharmD, FACC Assistant Professor of Medicine Duke University Medical Center
Should Gene+cs Influence Medica+on Use? Mona Fiuzat, PharmD, FACC Assistant Professor of Medicine Duke University Medical Center Popula(on Differences Gene(c informa(on of humans is 95-99% iden(cal The
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationPharmacogenomics: Increasing the safety and effectiveness of drug therapy
Pharmacogenomics: Increasing the safety and effectiveness of drug therapy Introduction to personalized medicine The goal of personalized medicine is to individualize health care by using knowledge of patients
More informationDeriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions!
Deriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions! Casey L. Overby 1,2, Beth Devine 1, Peter Tarczy-Hornoch 1, Ira Kalet
More informationBig Data Course Week 7 Test2Learn TM 5/7/16
The site is http://api.test2learn.com Usernames are first letter of first-name + first 3 letters of last name (i.e. John Smith would be jsmi ) Passwords are the same as the usernames. Everyone will need
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationAnti-cancer drugs. Introduction : Body : 1) Alkylating Agents
Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of
More informationVORAXAZE (glucarpidase) For Injection, for intravenous use Initial U.S. Approval: 2012
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VORAXAZE safely and effectively. See full prescribing information for VORAXAZE. VORAXAZE (glucarpidase)
More informationPersonalized Medicine in Real Time
LABORATORY OF PERSONALIZED HEALTH LPH Personalized Medicine in Real Time DNA-Guided Clopidogrel (Plavix ) Management Pharmacogenetic Foundations and Case Study 1 Clopidogrel (Plavix ) Leading AntiPlatelet
More informationCase Report Warfarin Dosing in a Patient with CYP2C9 3 3 and VKORC AA Genotypes
Case Reports in Genetics, Article ID 413743, 4 pages http://dx.doi.org/10.1155/2014/413743 Case Report Warfarin Dosing in a Patient with CYP2C9 3 3 and VKORC1-1639 AA Genotypes Mark Johnson, 1 Craig Richard,
More informationPerceived challenges in genomic-based drug development. Garret A. FitzGerald University of Pennsylvania
Perceived challenges in genomic-based drug development Garret A. FitzGerald University of Pennsylvania Genomics Based Personalization of Medicine A Case in Point in Cancer Aside from emerging resistance.
More informationCYP2D6 and the oestrogen receptor
Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/cyp2d6-and-the-oestrogenreceptor/ CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is
More informationDisclaimer. Learning Objectives. Key Therapeutic Area: Hematologic Malignancies Last Updated: 10 August /12/2012
Disclaimer Key Therapeutic Area: Hematologic Malignancies Last Updated: 10 August 2010 This presentation was supported by Grant Number IU38GD000070 from Centers for Disease Control and Prevention (CDC).
More informationPAIN MEDICATION DNA INSIGHT
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya, M.D. PAIN MEDICATION DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROESSIONAL Nilesh
More informationMethotrexate: is acute oral overdose ever a concern?
Methotrexate: is acute oral overdose ever a concern? Dr Betty Chan Emergency Physician & Clinical Toxicologist Prince of Wales Hospital New South Wales Poisons Information Centre Case Study 1 53F(80kg)
More information